Results 241 to 250 of about 138,725 (257)

Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

Nature Medicine, 2018
Jacqulyne Robichaux, Yasir Y Elamin, Zhi Tan   +2 more
exaly  

Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases

Cancer Cell, 2011
Wei Xu, Hui Yang, Ping Wang
exaly  

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

Journal of Clinical Oncology, 2018
Christina Lacchetti, Michael B Atkins, Ian Chau   +2 more
exaly  

The evolving landscape of tissue‐agnostic therapies in precision oncology

Ca-A Cancer Journal for Clinicians
Vivek Subbiah, Bettina Ryll, Razelle Kurzrock   +2 more
exaly  

JAK inhibitors—Friend or Foe?

The Lancet Rheumatology
openaire   +2 more sources

JAK inhibitors improve RA pain

Nature Reviews Rheumatology
openaire   +2 more sources

[JAK inhibitors in rheumatology].

La Revue du praticien, 2022
openaire   +1 more source

Understanding JAK inhibitor toxicity

Journal of the American Academy of Dermatology
Athira Sivadas, Kevin W. Byram, Manuel Valdebran, Tyler Beck   +3 more
openaire   +1 more source

Journal club: JAK inhibitors and safety

European Journal of Dermatology
Angel Rosell, Diaz, Tassilo, Dege, Inès, Chircop, Victoire, Reynaud, Niamh, Byrne, Am, Lé, Paloma, Garcia-Piqueras   +6 more
openaire   +2 more sources

JAK Inhibitors in RA

2017
openaire   +1 more source